For metastatic/advanced NSCLC patients who do not have targetable mutations, either
immunotherapy targeting the programmed death-1 and its ligand (PD-1/L1) pathway alone or in
combination with platinum doublet chemotherapy is now a standard of care. However, still
about half of the patients do not benefit due to treatment resistance. It is therefore
critically important to find novel therapies and combinations to benefit patients who have
failed or are intolerant to 1st line immunotherapy.
This study hypothesizes that ipatasertib in combination with taxane (e.g. docetaxel) can be
an effective strategy. Ipatasertib is a novel adenosine triphosphate (ATP)-competitive
inhibitor that has demonstrated robust and selective targeting of protein kinase B (PKB, also
known as AKT) in cancer patients. Importantly, evidence from preclinical studies has
demonstrated that AKT inhibitors (e.g. ipatasertib) can enhance the therapeutic effect of
chemotherapy as well as immunotherapy via modulating Phosphatidylinositol 3-kinase
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.